- VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing.
- The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
- VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
- The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats.
- VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
At a glance
- Company
- VERAXA Biotech
- Ticker
- NASDAQ: VRXA
- Announcement
- Product
- Location
- San Diego
Products and programs
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What did VERAXA report about its BiTAC-ADC platform?
The company said laboratory studies showed its BiTAC-ADC technology could distinguish breast cancer cells from healthy cells. It also reported dose-dependent destruction of three-dimensional tumor cell spheroids. These are early in vitro proof-of-concept findings; the release does not describe them as clinical results.
How is the BiTAC approach intended to improve antibody-based cancer therapies?
VERAXA describes its proprietary approach as designed to activate therapeutic effects only in targeted tumor cells. Its stated aim is to improve the precision of antibody-based treatments. The release presents this as the platform’s design goal, rather than evidence of effectiveness in patients.
What are antibody-drug conjugates and T-cell engagers?
An antibody-drug conjugate links an antibody that recognizes a target to a drug payload, aiming to deliver that payload to cells bearing the target. A T-cell engager is designed to bring a T cell into contact with a target cell, potentially helping the immune cell attack it.
What is VERAXA presenting at the BIO International Convention 2026?
The company said it plans to present its BiTAC-ADC and BiTAC-TCE platforms to potential strategic collaborators at the convention in San Diego. The release describes this as an opportunity to engage with prospective pharmaceutical and biotechnology partners; it does not announce a collaboration agreement.
SEC filings
- 6-KReport of a foreign issuer Filed
- 20-FAnnual report of a foreign issuer Filed
- SCHEDULE 13DSCHEDULE 13D Filed
- SCHEDULE 13DSCHEDULE 13D Filed
- SCHEDULE 13DSCHEDULE 13D Filed
- SCHEDULE 13DSCHEDULE 13D Filed
- 6-KReport of a foreign issuer Filed
- CERTCERT Filed
- 8-A12B/A8-A12B/A Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
